What is soft capsule gelatin?

Soft capsule gelatin is a hydrolyzed collagen protein derived from animal hides, bones, or skin, processed to pharmaceutical or food-grade standards and used specifically to form the flexible, seamless shell of softgel capsules. It differs from gelatin used in food applications primarily in its purity specifications, bloom strength range, and heavy-metal limits — all of which are tightly controlled to meet USP, EP, or JP pharmacopoeial standards.

The reason gelatin dominates softgel manufacturing comes down to a unique combination of properties no single synthetic polymer has yet fully replicated: it melts at body temperature, forms a homogenous film when cast at low concentrations, and seals cleanly under rotary die pressure. Actual production testing consistently shows that pharmaceutical gelatin with a bloom strength between 150 and 200 g produces shells with the best balance of flexibility and wall integrity for oil-based fills — a finding that holds across multiple encapsulation gelatin suppliers tested under controlled conditions.

In 2026, soft capsule gelatin remains the dominant material for liquid-filled capsules across the pharmaceutical and nutraceutical sectors, even as plant-based alternatives continue to gain shelf space. Its market relevance isn't just historical inertia — it reflects genuine performance advantages that formulators still rely on at commercial scale.

Why the shell material choice matters so much

The capsule shell is not a passive container. It controls dissolution rate, interacts chemically with the fill material, and determines shelf-life stability under temperature and humidity stress. Selecting the wrong capsule grade gelatin — particularly the wrong bloom strength or animal source — can produce fill leakage, cross-linking during storage, or regulatory non-compliance in target markets. These aren't edge-case risks. Industry stability data suggests that cross-linking-related dissolution failures account for a significant share of softgel batch rejections in commercial nutraceutical production.

Understanding what soft capsule gelatin is, technically and commercially, is therefore a prerequisite for anyone involved in oral dosage form development.

How it fits into the broader gelatin market

According to recent 2026 market data, the global gelatin market is valued at approximately $4.8 billion, with pharmaceutical gelatin — including soft capsule applications — representing more than 35% of that total. Softgel capsules account for roughly 30% of all oral liquid dosage forms globally, growing at a compound annual rate of around 6.5%. These figures reflect sustained demand, not a niche application.

How soft capsule gelatin is made

The manufacturing process for encapsulation gelatin is more complex than most buyers realize. The raw material — typically bovine hide, porcine skin, or fish skin — goes through a multi-stage extraction, purification, and quality-grading process before it reaches a softgel facility.

The extraction and processing sequence

1. Pre-treatment: Raw animal hides or bones are cleaned, defatted, and subjected to either acid treatment (Type A gelatin, typically porcine) or alkali treatment (Type B gelatin, typically bovine). The treatment type affects the final isoelectric point and viscosity profile.
2. Extraction: The pre-treated material is cooked in hot water through multiple extraction stages at progressively higher temperatures. Each successive extraction yields a lower bloom-strength fraction. Capsule grade gelatin typically uses the first or second extraction to achieve the required gel strength.
3. Filtration and purification: The gelatin solution passes through activated carbon filtration and ion exchange systems to remove impurities, color bodies, and trace metals. Heavy-metal limits for pharmaceutical gelatin are substantially stricter than food grade.
4. Concentration and sterilization: The clarified solution is evaporated under vacuum to increase solids content, then pasteurized to eliminate microbial contamination — a critical step for USP compliance.
5. Drying and milling: The concentrated gel is dried on stainless steel belts, then milled to a consistent particle size and packaged in moisture-protected containers for shipment to softgel manufacturers.

Each step in this sequence directly affects the final bloom strength, viscosity, and color of the gelatin capsule shells produced downstream. A change in pre-treatment duration of even a few hours can shift bloom strength by 20–30 g, which is why reputable suppliers provide lot-by-lot certificates of analysis rather than just product-level specifications.

Quality parameters measured at the gelatin plant

Before any batch ships, pharmaceutical gelatin producers test for bloom strength, viscosity (measured as millipascal-seconds in a standardized 6.67% solution at 60°C), pH, moisture content, sulfur dioxide residuals, and microbiological burden. These aren't just internal checkboxes — they map directly to pharmacopoeial monographs that regulatory agencies in the US, EU, and Japan audit during drug product inspections.

Types of gelatin used in softgel capsules

Not all gelatin capsule shells are made from the same source material. The animal origin determines not just the biochemical profile of the gelatin but also its regulatory classification, certifiable claims, and market positioning. Four distinct types are commercially relevant in 2026.

Porcine gelatin capsules

Porcine gelatin capsules are produced from pig skin and represent the highest-volume source globally. Porcine-derived Type A gelatin typically delivers more consistent bloom strength lot-to-lot compared to bovine sources, and its lower isoelectric point gives it better solubility behavior in certain acidic fill environments. Cost efficiency is a genuine advantage. For non-religious markets — which represent the majority of the US supplement industry — porcine gelatin is the default. The limitation is straightforward: it cannot be certified halal or kosher, which excludes it from a growing consumer segment.

Bovine gelatin capsules

Bovine gelatin capsules, sourced from cattle hide and bone, dominate halal and kosher-certified product lines. Type B bovine gelatin carries a higher isoelectric point and tends toward higher viscosity at equivalent bloom values — which can require adjustment in the softgel manufacturing ribbon formulation. BSE/TSE compliance documentation is non-negotiable for bovine material entering US and EU pharmaceutical supply chains, and in 2026, digital traceability systems are increasingly expected rather than optional. According to recent industry data, demand for certified bovine gelatin in nutraceutical capsules is growing at a faster rate than total market growth, driven directly by halal-labeling requirements in export markets.

Fish gelatin capsules

Fish gelatin capsules are derived from fish skin and scales — most commonly tilapia, pollock, or cod. They dissolve at lower temperatures than mammalian gelatins and are acceptable under both halal and kosher dietary laws, making them commercially attractive for dual-certified products. Why do many formulators still hesitate to use fish gelatin? The primary concern is cost: fish gelatin commands a meaningful price premium over porcine and bovine sources, and its lower gel-forming temperature can create manufacturing challenges on conventional softgel lines optimized for mammalian gelatin. It is not a vegan ingredient — a point worth clarifying explicitly, since fish gelatin is sometimes incorrectly marketed as a plant-based or vegetarian option.

Modified and specialty gelatins

Beyond the three primary animal sources, modified gelatins — such as succinylated gelatin — exist for niche applications where the standard shell interacts unfavorably with the fill. Succinylation alters the protein's charge profile, reducing incompatibility with certain ionic or polar fill materials. These are specialized procurement decisions, not standard catalog items, and they typically require direct technical collaboration with the gelatin supplier.

Bloom strength and viscosity: what the numbers mean

Gelatin bloom strength is arguably the most important single specification in softgel manufacturing — and also one of the most frequently misapplied. Bloom value measures gel stiffness: specifically, the force in grams required to depress a standardized plunger 4 mm into a 6.67% gelatin gel held at 10°C for 17 hours. Higher bloom equals a stiffer, stronger gel structure.

Choosing the right bloom value for your fill

A persistent industry misconception is that higher bloom strength is always preferable. Real-world encapsulation data tells a different story. For oil-based fills — omega-3 fatty acids, vitamin D in carrier oil, CoQ10 suspensions — a bloom range of 150–200 g typically produces optimal shell flexibility and seam integrity. Go higher than 250 g with a low-polarity oil fill and you risk brittle shells that crack under standard packaging and transportation stress. Conversely, aqueous or high-humidity-sensitive fills may benefit from higher bloom to maintain wall structure, but this must be balanced against the cross-linking risk that higher-protein-density shells introduce over time.

Viscosity is the second key specification. Measured as the flow resistance of a 6.67% solution at 60°C, viscosity affects ribbon formation speed and thickness uniformity on the rotary die machine. Bloom and viscosity are correlated but not identical — two lots with the same bloom value can differ significantly in viscosity, which is why both parameters should always appear on a certificate of analysis.

Cross-linking: the hidden stability risk

Cross-linking in gelatin capsule shells occurs when free aldehydes — most commonly from fill excipients, impurities, or packaging materials — react with the gelatin protein network during storage. The result is a hardened shell that fails pharmacopoeial dissolution testing even when the product appears visually intact. This is a well-documented failure mode in nutraceutical stability programs. Practical mitigation involves selecting fills with low aldehyde activity, using antioxidants where appropriate, and conducting accelerated stability studies at 40°C/75% relative humidity before committing to commercial packaging configurations.

"The selection of gelatin bloom strength is not a one-size-fits-all decision. Formulators must consider fill composition, processing conditions, and end-use stability requirements simultaneously. A mismatch at the specification stage is far more costly to fix post-manufacture than to prevent upstream." — Industry consensus from pharmaceutical encapsulation technical guidelines

Soft capsule gelatin vs. plant-based alternatives

Plant-based capsule materials — primarily hydroxypropyl methylcellulose (HPMC) and starch-based systems — have gained significant ground in the nutraceutical market since 2022. By 2026, they represent a meaningful share of new product launches in the US supplement channel. The question for formulators isn't whether plant-based options exist. It's whether they are the right fit for a specific product.

Where gelatin still leads

Soft capsule gelatin maintains clear advantages in several formulation scenarios. Its self-sealing behavior under rotary die manufacturing means softgel lines designed for gelatin can run at substantially higher speeds than HPMC softgel lines, which require modified sealing conditions and typically run slower. For fill materials requiring hermetic sealing against oxygen ingress — high-DHA omega-3s, sensitive fat-soluble vitamins — gelatin's lower oxygen transmission rate compared to HPMC gives it a genuine stability edge. Cost per capsule remains lower for gelatin at commercial scale, which matters considerably for high-volume products where margin is tight.

Just like a building's foundation determines its long-term structural integrity, the capsule shell material sets the ceiling on what's achievable in dissolution control, fill protection, and shelf-life extension. Choosing the wrong foundation creates problems no amount of formulation finesse downstream can fully correct.

Where plant-based alternatives are gaining ground

HPMC and starch-based softgels serve markets that gelatin structurally cannot: vegan-certified products, certain religious dietary requirements, and consumer segments where animal-derived ingredients are a purchasing barrier. For enteric soft capsules, HPMC's acid-resistance properties can simplify coating requirements compared to traditional gelatin-based enteric systems. Of course, plant-based capsules carry their own limitations — higher moisture sensitivity during manufacturing, narrower processing windows, and in some cases, slower dissolution at lower pH values. These are not trivial constraints in an industrial softgel manufacturing environment.

The 2026 market dynamic

The mainstream research consensus in 2026 is that gelatin and plant-based capsule systems will coexist as complementary platforms rather than one displacing the other. Consumer demand for vegan options is real and growing, but pharmaceutical and high-potency nutraceutical applications continue to favor gelatin for its proven performance profile, pharmacopoeial anchoring, and supply chain maturity.

Regulatory and certification requirements

Regulatory compliance for soft capsule gelatin operates on multiple levels simultaneously: pharmacopoeial quality standards, animal-sourcing safety regulations, and religious or dietary certification schemes. Failing on any one layer can block market access or trigger a product recall.

Pharmacopoeial standards

In the US, pharmaceutical gelatin must conform to the USP monograph for Gelatin, which specifies limits for heavy metals, sulfur dioxide, microbial contamination, viscosity, and gel strength. Products marketed as dietary supplements fall under FDA 21 CFR Part 111 cGMP requirements, which extend quality obligations to incoming raw material testing and supplier qualification. Drug products are additionally subject to IND or NDA submission documentation that may require full characterization of the gelatin source and processing history.

European Union regulations add BSE/TSE risk assessment requirements tied to the animal source country of origin, with specific geographic restrictions on bovine materials from certain regions. Japan's JP monograph carries parallel specifications. Formulators targeting multi-market distribution need a gelatin supplier that can provide documentation against all three pharmacopoeias simultaneously — not an assumption that compliance with one implies compliance with others.

Halal, kosher, and identity-preserved sourcing

Halal certification for bovine gelatin capsules requires third-party audit of the slaughter process, facility segregation from non-halal materials, and ongoing supply chain monitoring. Kosher certification carries similar auditing requirements. The documentation burden is substantial, and the certification is only as reliable as the audit organization issuing it. In actual sourcing practice, it is common to encounter suppliers offering self-declared halal status without accredited third-party certification — a distinction that matters enormously when marketing to observant Muslim or Jewish consumers in the US or for export markets in the Middle East and Southeast Asia.

Emerging 2026 compliance requirements

Supply chain transparency is no longer an optional differentiator — it is becoming a compliance baseline. Carbon footprint disclosure requirements in EU export channels, FDA's Drug Supply Chain Security Act traceability provisions, and growing retailer ESG audit programs are all pushing gelatin buyers toward suppliers with digital traceability infrastructure. A supplier that cannot provide farm-of-origin data, processing plant audit records, and lot-level traceability documentation in 2026 represents a procurement liability, not just a quality gap.

Key sourcing criteria for 2026

Sourcing decisions for capsule grade gelatin in 2026 involve more variables than a simple price-per-kilogram comparison. Based on current industry procurement practice, five criteria consistently separate suppliers that create value from those that create risk.

Technical specification consistency

Lot-to-lot consistency in bloom strength and viscosity is the most operationally critical factor for a softgel manufacturing facility. A supplier whose bloom values vary by more than ±15 g between lots forces constant adjustment of the ribbon formulation on the encapsulation line, reducing throughput and increasing out-of-specification shell events. Request historical CoA data for at least 10 consecutive lots before approving a new gelatin supplier. Averages are less informative than standard deviations across the data set.

Audit and documentation capability

A qualified pharmaceutical gelatin supplier should be able to provide: a current Drug Master File (DMF) filed with the FDA, BSE/TSE certificates from a recognized authority, third-party halal or kosher certification where applicable, and a completed supplier questionnaire addressing cGMP compliance. Suppliers that resist site audits or cannot produce current DMF reference numbers should be disqualified regardless of price competitiveness.

Supply chain resilience and geographic diversification

The 2020–2022 supply disruption period exposed the risk of single-source gelatin procurement. In 2026, leading nutraceutical manufacturers maintain qualified dual-source supplier programs, with at least one domestic or near-shore qualified source to reduce lead time risk. The global pharmaceutical gelatin supply base is relatively concentrated — a disease outbreak in a major livestock-producing region or a regulatory action against a key processing facility can create rapid price spikes and allocation constraints. Geographic diversification in your qualified supplier list is genuine risk management, not procurement excess.

Regulatory documentation readiness

For drug product applications, the gelatin supplier's DMF must be current and accessible for FDA reference during application review. Gaps in DMF maintenance — particularly outdated process descriptions or unresolved FDA correspondence — can delay approval timelines for the finished drug product. Confirm DMF status directly with the FDA's public DMF database before initiating formal supplier qualification.

Sustainability and traceability positioning

Consumer and retailer pressure for sustainable sourcing is translating into procurement requirements in the US supplement industry. Some major retailers now require suppliers to complete environmental and social governance (ESG) questionnaires that cascade down to raw material suppliers, including gelatin. In 2026, a gelatin supplier that can provide verified country-of-origin data, processing facility environmental compliance records, and a published sustainability policy is better positioned to support its customers through these requirements than one operating without this infrastructure.

Selecting the right soft capsule gelatin partner is ultimately a strategic decision that touches quality, regulatory, commercial, and reputational dimensions simultaneously. The technical specifications matter enormously — but so does the supplier's ability to support you through audits, regulatory submissions, and the ongoing compliance demands of an increasingly transparent supply chain environment.

Frequently asked questions

Soft capsule gelatin is a technically complex, commercially significant material that warrants the same rigorous supplier qualification and specification discipline applied to active pharmaceutical ingredients. In 2026, the sourcing environment adds supply chain transparency and sustainability requirements on top of the traditional quality and regulatory baseline. Formulators and procurement teams who approach soft capsule gelatin with that full-spectrum perspective will be better positioned to avoid the batch failures, regulatory setbacks, and supply disruptions that continue to affect operations that treat it as a commodity input.